Diabetic Macular Edema – Epidemiology – Emerging Markets

Clarivate Epidemiology’s coverage of diabetic macular edema (DME) comprises epidemiological estimates of key patient populations in 45 countries. We report the prevalence of DME for each country, as well as annualized case counts projected to the national population.

In addition to forecasting prevalent patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapy in the major mature pharmaceutical markets.

Clarivate Epidemiology’s DME forecast will answer the following questions:

• Of all people with DME, how many in each country have been formally diagnosed?
• Of all people diagnosed with DME, how many in each of the major mature pharmaceutical markets are drug-treated?
• How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of DME over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In total, Clarivate Epidemiology forecasts the following nine DME patient populations:

• Total prevalent cases.
• DME with mild nonproliferative diabetic retinopathy.
• DME with moderate nonproliferative diabetic retinopathy.
• DME with severe nonproliferative diabetic retinopathy.
• DME with proliferative diabetic retinopathy.
• Diagnosed prevalent cases.
• Undiagnosed prevalent cases.
• Diagnosed drug-treated cases.
• Diagnosed non-drug-treated cases.

Note: Coverage may vary by country.